Lexicon Pharmaceuticals (LXRX)
NASDAQ:LXRX
Want to see LXRX full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.05Last Year’s EPS
0.01Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized substantial progress across multiple fronts: large milestone-driven revenue, meaningful improvements in net loss, a stronger liquidity position, and clear clinical development milestones (SONATA enrollment completion mid-2026; Zynquista NDA resubmission midyear; LX9851 in Phase I; pilavapadin Phase III readiness). At the same time, several risks remain: the revenue uplift was largely one-time milestone-driven with limited organic sales, continued dependence on partners and conditional debt tranches, regulatory and enrollment uncertainties, and competitive dynamics in HCM. On balance, the highlights — particularly financial strengthening and late-stage program momentum — outweigh the lowlights, though execution risk into the second half of 2026 remains important.Company Guidance
Significant Revenue Increase Driven by Milestones
Total revenue of $21.1M in Q1 2026 versus $1.3M in Q1 2025, an increase of ~1,523%, driven primarily by two $10M milestone payments from Novo Nordisk; INPEFA net sales contributed $1.1M.
Major Reduction in Net Loss
Net loss improved to $1.0M (less than $0.01 per share) in Q1 2026 from a net loss of $25.3M ($0.07 per share) in Q1 2025, representing a ~96.1% reduction in the loss magnitude.
Strengthened Balance Sheet and Liquidity
Cash, cash equivalents, short-term investments and restricted cash increased to $199.7M as of March 31, 2026 from $125.2M as of Dec 31, 2025, an increase of $74.5M (~59.5%). Total debt decreased to $49.7M from $54.0M (down ~8.0%). Announced a $100M debt facility with Hercules (initial $55M funded), providing additional financial flexibility.
Operational Discipline and Lower Operating Expenses
R&D expenses decreased to $12.8M from $15.3M year-over-year (down ~16.3%). SG&A decreased to $9.2M from $11.6M (down ~20.7%). Company highlighted a $4.8M quarter-over-quarter reduction in operating expenses attributable to strategic repositioning and cost discipline.
Progress on Key Late-Stage Programs — Sotagliflozin
SONATA-HCM Phase III trial enrollment on track for completion mid-2026 (target ~500 patients across ~130 sites in 20 countries); topline data anticipated Q1 2027. Zynquista (T1D) NDA resubmission targeted midyear 2026 using STENO1 investigator-initiated data, with potential approval in 2026.
LX9851 Advances Into Clinical Development
LX9851 (ACSL5 inhibitor for obesity) entered Phase I in March under Novo Nordisk, triggering a $10M milestone (part of the two $10M milestones recognized). Novo Nordisk's initiation demonstrates partner progress and validation of the asset.
Pilavapadin: Regulatory Progress and Phase III Readiness for DPNP
Pilavapadin met regulatory objectives and PROGRESS-3 Phase IIb data supported selection of 10 mg for Phase III in DPNP; additional preclinical data presented supporting expanded neuroscience opportunities (e.g., spasticity). Company is seeking a strategic partner to advance late-stage development without dilution.
Global Commercial Progress for SOTA
Licensee Viatris has filed regulatory applications for sotagliflozin in heart failure across additional markets and launched in the UAE, indicating international commercialization progress.
LXRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LXRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $1.60 | $1.68 | +5.00% |
Mar 05, 2026 | $1.63 | $1.64 | +0.61% |
Nov 06, 2025 | $1.38 | $1.43 | +3.62% |
Aug 06, 2025 | $1.05 | $1.15 | +9.52% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Lexicon Pharmaceuticals (LXRX) report earnings?
Lexicon Pharmaceuticals (LXRX) is schdueled to report earning on Jul 30, 2026, Before Open (Confirmed).
What is Lexicon Pharmaceuticals (LXRX) earnings time?
Lexicon Pharmaceuticals (LXRX) earnings time is at Jul 30, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LXRX EPS forecast?
LXRX EPS forecast for the fiscal quarter 2026 (Q2) is -0.05.